Global Veterinary CRO and CDMO Market Offering Strategic Growth Insights for Businesses from 2026–2030

April 8, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Arthritis Monoclonal Antibodies Market At The End Of The 2026–2030 Forecast Period?

The veterinary cro and cdmo market size has experienced robust growth in recent years. Projections indicate a rise from $7.53 billion in 2025 to $8.2 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.9%. Historically, this expansion has been driven by factors such as the restricted in-house research and development capacities of veterinary firms, an increasing population of companion animals, the growing incidence of animal diseases, the early integration of cdm/o services in advanced economies, and the demand for novel veterinary biologics and drugs.

The veterinary CRO and CDMO market is anticipated to show robust expansion over the next few years. It is projected to achieve a size of $11.81 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.6%. The expansion during this forecast period is primarily driven by the escalating demand for contract research and manufacturing services, ongoing technological advancements in veterinary drug development, the growth of veterinary biologics and pharmaceuticals, an increase in global regulatory compliance requirements, and the rising adoption of precision medicine for animals. Significant trends expected in the forecast period encompass the increasing outsourcing of veterinary drug development, the expansion of preclinical and clinical trial services, a growing need for regulatory consulting services, the adoption of advanced analytical and formulation services, and a heightened focus on post-marketing surveillance and pharmacovigilance.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12080&type=smp

Which Market Drivers Are Supporting The Expansion Of The Arthritis Monoclonal Antibodies Market?

The veterinary CRO and CDMO market is anticipated to experience growth driven by increasing pet ownership in the coming years. Pet ownership signifies the role of an individual or household as the primary caregiver, responsible for the welfare and control of a domesticated animal, involving a lasting, legal, and moral obligation. This rise in pet ownership stems from a greater recognition of the emotional and health benefits pets provide, as people actively pursue companionship, relief from stress, and enhanced overall well-being through pet care. The veterinary CRO and CDMO market benefits from this trend, as the expanding number of pets generates demand for the creation and manufacturing of veterinary pharmaceuticals, vaccines, and treatments necessary for ensuring pet health and safety. Illustratively, in March 2025, the American Pet Products Association, a US-based non-profit association, reported that ninety-four (94) million U.S. households own at least one pet, an increase from eighty-two (82) million in 2023. Therefore, the ongoing rise in pet ownership is expected to stimulate the veterinary CRO and CDMO market moving forward.

What Segment Types Make Up The Arthritis Monoclonal Antibodies Market?

The veterinary cro and cdmo market covered in this report is segmented –

1) By Service Type: Discovery, Development, Manufacturing, Packaging And Labeling, Market Approval And Post-marketing

2) By Animal Type: Companion Animals, Livestock Animals

3) By Application: Medicines, Medical Devices, Pharmaceuticals, Biologics, Other Applications

Subsegments:

1) By Discovery: Target Identification, Target Validation, Lead Identification, Lead Optimization

2) By Development: Preclinical Development, Clinical Development (Phase I, II, III), Regulatory Consulting

3) By Manufacturing: API Manufacturing, Finished Dose Formulation, Analytical Services

4) By Packaging And Labeling: Primary Packaging, Secondary Packaging, Label Design And Compliance

5) By Market Approval And Post-marketing: Regulatory Submissions, Pharmacovigilance, Post-marketing Surveillance

Which Market Trends Are Creating New Opportunities In The Veterinary CRO And CDMO Market?

Key entities active in the veterinary CRO and CDMO market are concentrating on developing novel services, including integrated multi-site CDMO networks equipped with advanced sterile manufacturing, lyophilization, and specialized dosage capabilities. This focus aims to simplify drug development processes and accelerate compliant commercialization. Integrated multi-site CDMO networks represent cohesive platforms that combine multiple manufacturing sites and specific technologies, such as sterile multidose systems, lyophilization, and flexible packaging, all governed by harmonized operational and quality frameworks to provide complete pharmaceutical development and production solutions. For example, in April 2025, Meribel Pharma Solutions, a UK-based full-service CDMO offering drug development, formulation, analytical services, sterile and semi-solid manufacturing, and packaging solutions, initiated its operations. This launch included a network of 13 facilities spread across France, Spain, and Sweden, intended to support products from early development through to commercial-scale production. The company provides specialized expertise in oral solid dose, preservative-free multidose, and lyophilization technologies for both human and veterinary health products.

Who Are The Key Players Driving Competition In The Arthritis Monoclonal Antibodies Market?

Major companies operating in the veterinary cro and cdmo market are Eurofins Scientific SE, Charles River Laboratories Inc., IDEXX Laboratories Inc., Elanco India Private Limited, Aenova Group, Taconic Bioscience Inc., knoell Germany GmbH, ClinVet International Pty Ltd., VetPharm Inc., Vetio Animal Health Company, Ridgeway Research Ltd., Drayton Animal Health Ltd., KLIFOVET GmbH, Cebiphar, Veterinary Research Management (VRM) Ltd., Vetspin Srl, STATKING Animal Health CRO, Arcoblu S.r.l., Syneos Health Inc., Pharmaceutical Product Development Inc., Inotiv Inc., Promega Corporation, Triveritas Ltd.

Read the full veterinary cro and cdmo market report here:

https://www.thebusinessresearchcompany.com/report/veterinary-cro-and-cdmo-global-market-report

How Is The Arthritis Monoclonal Antibodies Market Distributed Across Key Geographic Regions?

North America was the largest region in the veterinary CRO and CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary cro and cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Arthritis Monoclonal Antibodies Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12080&type=smp

Browse Through More Reports Similar to the Global Veterinary CRO And CDMO Market 2026, By The Business Research Company

Biologics Cdmo Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Healthcare Cro Services Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/healthcare-cro-services-global-market-report

Preclinical Cro Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/preclinical-cro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795